Spots Global Cancer Trial Database for CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma
Official Title: CEV With/Without Periocular Carboplatin Chemotherapy for Nonmetastatic Extraocular Retinoblastoma Carboplatin--A Single Center, Retrospective Study to Evaluate the Efficacy of Carboplatin in Subjects With Retinoblastoma
Study ID: NCT02319486
Conditions
Study Description
Brief Summary: This study will evaluate a uniform chemotherapy protocol for nonmetastatic extraocular retinoblastoma
Detailed Description: This study will be a phase 4 open label interventional case series. Patients with retinoblastoma will be receive chemotherapy with or without periocular injections of carboplatin at a dose of 20mg/2 ml. Patients will receive chemotherapy on a monthly basis for a total duration of therapy of 6 months. Patients will be followed for 18 months .
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Huasheng Yang, M.D, PHD
Affiliation: Zhongshan Ophthalmic Center, Sun Yat-sen University
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
